Brain cancer
HealthNew drug combination boosts life expectancy from grade 3 brain tumors by 45% or more
A new drug combination extends survival for patients with recurrent grade 3 astrocytoma, offering rare hope in aggressive brain cancer care.
Joseph Shavit
